ALLK vs. GOSS, EBS, ERAS, VERV, TBPH, LXRX, ESPR, SLRN, FBLG, and CTNM
Should you be buying Allakos stock or one of its competitors? The main competitors of Allakos include Gossamer Bio (GOSS), Emergent BioSolutions (EBS), Erasca (ERAS), Verve Therapeutics (VERV), Theravance Biopharma (TBPH), Lexicon Pharmaceuticals (LXRX), Esperion Therapeutics (ESPR), Acelyrin (SLRN), FibroBiologics (FBLG), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical preparations" industry.
Gossamer Bio (NASDAQ:GOSS) and Allakos (NASDAQ:ALLK) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, community ranking, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.
Gossamer Bio has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Allakos has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
Gossamer Bio's return on equity of -99.88% beat Allakos' return on equity.
In the previous week, Allakos had 4 more articles in the media than Gossamer Bio. MarketBeat recorded 6 mentions for Allakos and 2 mentions for Gossamer Bio. Allakos' average media sentiment score of 1.52 beat Gossamer Bio's score of 0.26 indicating that Gossamer Bio is being referred to more favorably in the media.
Allakos received 36 more outperform votes than Gossamer Bio when rated by MarketBeat users. However, 65.32% of users gave Gossamer Bio an outperform vote while only 59.34% of users gave Allakos an outperform vote.
Gossamer Bio is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks.
Gossamer Bio currently has a consensus target price of $7.65, suggesting a potential upside of 1,196.61%. Allakos has a consensus target price of $1.83, suggesting a potential upside of 46.67%. Given Allakos' stronger consensus rating and higher probable upside, equities analysts clearly believe Gossamer Bio is more favorable than Allakos.
81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 84.6% of Allakos shares are held by institutional investors. 5.0% of Gossamer Bio shares are held by company insiders. Comparatively, 16.1% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Gossamer Bio beats Allakos on 9 of the 15 factors compared between the two stocks.
Get Allakos News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
